# Amarin Corp Plc\\uk: overview

AMRN · Nasdaq · CIK 897448 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amrn.md) · [Financials](/companies/amrn/financials.md) · [Filings](/companies/amrn/filings.md) · [Insiders](/companies/amrn/insiders.md)

Latest reported revenue: [$39.5m](/filings/0001193125-26-435082.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-435082).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [62.3 d](/filings/0001193125-26-085818.md) | [42.0](/filings/0001193125-26-188940.md) | [72.7](/filings/0001193125-26-323845.md) | [49.7](/filings/0001193125-26-435082.md) | [49.2 d](/filings/0001193125-26-085818.md) | [45.1](/filings/0001193125-26-188940.md) | [42.2](/filings/0001193125-26-323845.md) | [39.6](/filings/0001193125-26-435082.md) |
| Gross margin | % | [(15.4%) d](/filings/0001193125-26-085818.md) | [59.8%](/filings/0001193125-26-188940.md) | [69.2%](/filings/0001193125-26-323845.md) | [44.7%](/filings/0001193125-26-435082.md) | [47.1% d](/filings/0001193125-26-085818.md) | [39.4%](/filings/0001193125-26-188940.md) | [35.5%](/filings/0001193125-26-323845.md) | [40.9%](/filings/0001193125-26-435082.md) |
| Operating margin | % | [(84.3%) d](/filings/0001193125-26-085818.md) | [(39.9%)](/filings/0001193125-26-188940.md) | [(22.0%)](/filings/0001193125-26-323845.md) | [(22.4%)](/filings/0001193125-26-435082.md) | [(12.9%) d](/filings/0001193125-26-085818.md) | [(25.1%)](/filings/0001193125-26-188940.md) | [(28.5%)](/filings/0001193125-26-323845.md) | [(6.0%)](/filings/0001193125-26-435082.md) |
| Net margin | % | [(78.0%) d](/filings/0001193125-26-085818.md) | [(37.4%)](/filings/0001193125-26-435082.md) | [(19.4%)](/filings/0001193125-26-435082.md) | [(15.6%)](/filings/0001193125-26-435082.md) | [(2.5%) d](/filings/0001193125-26-085818.md) | [(23.3%)](/filings/0001193125-26-435082.md) | [(18.1%)](/filings/0001193125-26-435082.md) | [0.6%](/filings/0001193125-26-435082.md) |
| Diluted EPS | $ per share | not reported | [(0.04)](/filings/0001193125-26-188940.md) | [(0.03)](/filings/0001193125-26-323845.md) | [(0.02)](/filings/0001193125-26-435082.md) | not reported | [(0.03)](/filings/0001193125-26-188940.md) | [(0.02)](/filings/0001193125-26-323845.md) | [0.00](/filings/0001193125-26-435082.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [583](/filings/0000950170-24-022636.md) | [369](/filings/0000950170-25-037620.md) | [307](/filings/0001193125-26-085818.md) | [229](/filings/0001193125-26-085818.md) | [214](/filings/0001193125-26-085818.md) |
| Gross margin | % | [79.2%](/filings/0000950170-24-022636.md) | [65.7%](/filings/0000950170-25-037620.md) | [53.9%](/filings/0001193125-26-085818.md) | [35.6%](/filings/0001193125-26-085818.md) | [56.6%](/filings/0001193125-26-085818.md) |
| Operating margin | % | [1.8%](/filings/0000950170-24-022636.md) | [(28.7%)](/filings/0000950170-25-037620.md) | [(22.0%)](/filings/0001193125-26-085818.md) | [(40.2%)](/filings/0001193125-26-085818.md) | [(23.5%)](/filings/0001193125-26-085818.md) |
| Net margin | % | [1.3%](/filings/0000950170-24-022636.md) | [(28.7%)](/filings/0000950170-25-037620.md) | [(19.3%)](/filings/0001193125-26-085818.md) | [(35.9%)](/filings/0001193125-26-085818.md) | [(18.2%)](/filings/0001193125-26-085818.md) |
| Diluted EPS | $ per share | [0.02](/filings/0000950170-24-022636.md) | [(0.26)](/filings/0000950170-25-037620.md) | [(0.15)](/filings/0001193125-26-085818.md) | [(0.20)](/filings/0001193125-26-085818.md) | [(0.09)](/filings/0001193125-26-085818.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/amrn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Sarissa Capital Management LP](/funds/1577524.md) | 2026-06-30 | $26.7m | 1,673,395 |  | Unchanged |
| [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $8.5m | 532,982 |  | Added +60,600 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $3.6m | 223,617 |  | Reduced −69,555 |
| [Waterfront Wealth Inc.](/funds/1775210.md) | 2026-06-30 | $3.2m | 213,949 |  | Added +10,611 |
| [Brooklands Fund Management Ltd](/funds/2036388.md) | 2026-06-30 | $2.7m | 177,325 |  | New +177,325 |
| [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $2.3m | 145,296 |  | Reduced −2,419 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.8m | 115,808 |  | Reduced −184,728 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $1.6m | 100,511 |  | Reduced −7,031 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $1.5m | 95,364 |  | Added +14,789 |
| [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $1.1m | 71,813 |  | Reduced −3,690 |

## Recent filings

[All 1,251 filings](/companies/amrn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 07:05 ET | [10-Q](/filings/0001193125-26-435082.md) | Quarterly report, period 2026-09-30 | 0001193125-26-435082 |
| 2026-10-28 | 07:05 ET | [8-K](/filings/0001193125-26-435081.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-435081 |
| 2026-08-27 | 18:56 ET | [SCHEDULE 13D/A](/filings/0000899140-26-000972.md) | Ownership report, active investor, amended | 0000899140-26-000972 |
| 2026-07-29 | 16:30 ET | [10-Q](/filings/0001193125-26-323845.md) | Quarterly report, period 2026-06-30 | 0001193125-26-323845 |
| 2026-07-29 | 16:30 ET | [8-K](/filings/0001193125-26-323841.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-323841 |
| 2026-05-15 | 21:30 ET | [8-K](/filings/0001193125-26-224771.md) | 5.07 Shareholder vote results | 0001193125-26-224771 |
| 2026-04-29 | 07:06 ET | [10-Q](/filings/0001193125-26-188940.md) | Quarterly report, period 2026-03-31 | 0001193125-26-188940 |
| 2026-04-29 | 07:05 ET | [8-K](/filings/0001193125-26-188935.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-188935 |
| 2026-04-10 | 17:00 ET | [DEF 14A](/filings/0001193125-26-151417.md) | Proxy statement, period 2026-04-10 | 0001193125-26-151417 |
| 2026-03-27 | 17:00 ET | [8-K](/filings/0001193125-26-129334.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-129334 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-085818.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/cda034c1-2e95-43b8-808a-ec17e007989e)

## About the filer

- CIK: 897448
- Tickers: AMRN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: X0
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 08:23 ET. No prices; not investment advice.